Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy

被引:190
作者
Dreher, MR
Raucher, D
Balu, N
Colvin, OM
Ludeman, SM
Chilkoti, A [1 ]
机构
[1] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA
[2] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA
[3] Duke Univ, Med Ctr, Ctr Comprehens Canc, Durham, NC 27710 USA
[4] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
关键词
thermally responsive polymer; elastin-like polypeptide; drug delivery; doxorubicin; controlled release;
D O I
10.1016/S0168-3659(03)00216-5
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Thermally responsive elastin-like polypeptides (ELPs) were synthesized by recombinant DNA techniques and conjugated to doxorubicin through an acid-labile hydrazone bond to enable release of the drug in the acidic environment of lysosomes. The thermal properties, intracellular localization and cytotoxicity of the conjugate were investigated in this study. The conjugation procedure resulted in a mixed population of free ELP and ELP-doxorubicin (ELP-dox) conjugates that exhibit a broader transition than the parent ELP. A simple centrifugation procedure was developed to purify the ELP-dox conjugate from other reactants and resulted in a sharper thermal transition, similar to the parent ELP. The ELP was endocytosed by squamous cell carcinoma cells (FaDu) and trafficked into lysosomes, as observed by the colocalization of the ELP with a lysosome-specific dye through confocal fluorescence microscopy. Interestingly, both the ELP-dox conjugate and free drug exhibited near equivalent in vitro cytotoxicity, although their subcellular localization was significantly different. The free drug was largely concentrated in the nucleus, while the conjugate was dispersed throughout the cytoplasm with limited nuclear accumulation. These differences are significant because they suggest a different mechanism of cytotoxicity for the conjugate as compared with the free drug. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:31 / 43
页数:13
相关论文
共 51 条
  • [1] Liposomal drug formulations - Rationale for development and what we can expect for the future
    Allen, TM
    [J]. DRUGS, 1998, 56 (05) : 747 - 756
  • [2] ADRIAMYCIN(HYDRAZONE)-ANTIBODY CONJUGATES REQUIRE INTERNALIZATION AND INTRACELLULAR ACID-HYDROLYSIS FOR ANTITUMOR-ACTIVITY
    BRASLAWSKY, GR
    KADOW, K
    KNIPE, J
    MCGOFF, K
    EDSON, M
    KANEKO, T
    GREENFIELD, RS
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 33 (06) : 367 - 374
  • [3] Chabner B. A., 2001, Cancer Chemotherapy and Biotherapy: Principles and Practice, V3rd ed
  • [4] Targeted drug delivery by thermally responsive polymers
    Chilkoti, A
    Dreher, MR
    Meyer, DE
    Raucher, D
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (05) : 613 - 630
  • [5] Synthesis of HPMA copolymer containing adriamycin bound via an acid-labile spacer and its activity toward human ovarian carcinoma cells
    Choi, WM
    Kopecková, P
    Minko, T
    Kopecek, J
    [J]. JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, 1999, 14 (06) : 447 - 456
  • [6] Reversibly thermo-responsive alkyl-terminated poly(N-isopropylacrylamide) core-shell micellar structures
    Chung, JE
    Yokoyama, M
    Suzuki, K
    Aoyagi, T
    Sakurai, Y
    Okano, T
    [J]. COLLOIDS AND SURFACES B-BIOINTERFACES, 1997, 9 (1-2) : 37 - 48
  • [7] Conjugate of doxorubicin with a thermosensitive polymer drug carrier
    Chytry, V
    Ulbrich, K
    [J]. JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, 2001, 16 (06) : 427 - 440
  • [8] EXAMINATION BY LASER-SCANNING CONFOCAL FLUORESCENCE IMAGING MICROSCOPY OF THE SUBCELLULAR-LOCALIZATION OF ANTHRACYCLINES IN PARENT AND MULTIDRUG-RESISTANT CELL-LINES
    COLEY, HM
    AMOS, WB
    TWENTYMAN, PR
    WORKMAN, P
    [J]. BRITISH JOURNAL OF CANCER, 1993, 67 (06) : 1316 - 1323
  • [9] THE MOLECULAR PHARMACOLOGY OF DOXORUBICIN INVIVO
    CUMMINGS, J
    ANDERSON, L
    WILLMOTT, N
    SMYTH, JF
    [J]. EUROPEAN JOURNAL OF CANCER, 1991, 27 (05) : 532 - 535
  • [10] DRUG POLYMER CONJUGATES - POTENTIAL FOR IMPROVED CHEMOTHERAPY
    DUNCAN, R
    [J]. ANTI-CANCER DRUGS, 1992, 3 (03) : 175 - 210